April 18 (Reuters) - Cerevel Therapeutics said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial. (Reporting by Sriparna Roy in Bengaluru; Editing by Savio D'Souza)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.16 USD | -0.44% | -0.07% | -0.57% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.57% | 7.72B | |
+9.29% | 114B | |
+11.35% | 104B | |
-13.84% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.22% | 17.89B | |
+7.68% | 14.28B | |
+34.47% | 12.55B |
- Stock Market
- Equities
- CERE Stock
- News Cerevel Therapeutics Holdings, Inc.
- Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study